Gene therapy in human CD34+ HSPCs could prevent the infection of susceptible cells because HSPCs give rise to all blood cell types in HIV-1 pathogenesis, including CD4+ T cells, macrophages, dendritic cells, and microglia. Here, CD4 is linked to infection.